This cancer nanovaccine was subcutaneously injected on HER2+ breast tumor-bearing mice and generated CD4+ and CD8+ immune responses, IFN-γ secretion, and a significant decrease of tumor growth and increase of life expectancy. The gene discussed is ERBB2; the disease is neoplasm.